Compass Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Compass Therapeutics, Inc. on April 26, 2022, reporting events occurring on April 22, 2022, and April 25, 2022. The Company is a biopharmaceutical firm focused on developing therapies for rare diseases, listed on the NASDAQ Capital Market under the symbol CMPX.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
- Board Appointments: On April 25, 2022, the Board appointed Ellen Chiniara, J.D., and Mary Ann Gray, Ph.D., as new independent Class I directors. Their terms expire at the 2024 annual meeting.
- Director Departure: On April 22, 2022, Miranda Toledano, M.B.A., notified the Company of her decision not to stand for reelection at the May 24, 2022, Annual Meeting. Her departure is not due to any disagreement with the Company.
- Compensation Arrangements: The new directors will receive a $45,000 annual cash retainer and an initial option award to purchase 45,000 shares of common stock, vesting monthly over four years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of material risks and contingencies. The departure of Ms. Toledano is explicitly stated as unrelated to any disagreement regarding the Company's operations, policies, or practices.
Key Facts for Investor Verification
- Verify the independence status of the newly appointed directors, Ellen Chiniara and Mary Ann Gray, under Nasdaq Listing Rules.
- Confirm the vesting schedule and exercise price of the 45,000 share option grants awarded to the new directors.
- Monitor the composition of the Board following the departure of Miranda Toledano at the May 24, 2022, Annual Meeting.
- Review the Company's most recent 10-K or 10-Q for financial performance data, as this 8-K does not provide financial metrics.